Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.

Authors

Institutions

Publication Details

Journal
Drug Safety
Published
2026-01-14
DOI
https://doi.org/10.1007/s40264-025-01646-2
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

Saad Shakir, Denise Morris, Alison Yeomans, Manfred Hauben et al.
Drug Safety
Pharmacovigilance and Adverse Drug Reactions
article

Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

Saad Shakir, Denise Morris, Alison Yeomans, Manfred Hauben, Samantha Lane, Amy Bobbins, Dawn Cooper, Harriet Dickinson, Taylor Aurelius, Florence van Hunsel, Manal Younus, Eugene van Puijenbroek
article en

Abstract

A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.

Drug Safety
Merck KGaA, Darmstadt (Germany) (DE), University of Groningen (NL), New York Medical College (US), Ministry of Health (IQ), Gilead Sciences (United Kingdom) (GB), Netherlands Pharmacovigilance Centre Lareb (NL), Drug Safety Research Unit (GB), University of Portsmouth (GB)
Industry, innovation and infrastructure, Partnerships for the goals
Openalex Percentile: Top 88%
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.